TruSpine has been independently selected to present at the Healthtech Summit in June 2017, and has been cited as one of the 20 most promising Med Tech companies in Europe. The selection process involved 300 individual company assessments of more than 130 applications made by 30 members of a stellar Selection Committee within the past few months.
To be clear, this is an opportunity that cannot be purchased, as companies are selected entirely on Merit. In fact there is no charge for the company to present at the summit.
Pierre Chauvineau, of Boston Scientific (Hertfordshire, GB) is President of the summit, whose mission is to “Improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less-invasive medical devices and procedures”, a statement that is clearly absolutely aligned with TruSpine’s own philosophy and products. We believe that TruSpine’s independent selection is testament to the company’s program of development of disruptive and innovative and disruptive technology, and clearly shows that the company has already been noted in the international Med Tech arena.
The event has a comprehensive programme over 3 days that will see a balanced and varied succession of corporate presentations, interactive plenary sessions on opportunities related to accelerating investment as well as dedicated networking sessions, and a keynote speech by Rob ten Hoedt, Executive Vice President and President (EMEA Region), Medtronic.
The summit will provide TruSpine with a raft of opportunities to connect with both investors, as well as being in the spotlight as a potential acquisition target, with many well know potential suitors in attendance.